News · 26 weeks66-12%
2026-04-192026-10-11
Mix2690d
- Insider11(42%)
- SEC Filings7(27%)
- Other4(15%)
- Leadership2(8%)
- Earnings1(4%)
- Analyst1(4%)
Latest news
25 items- ANALYSTTruist initiated coverage on Alkermes Plc with a new price targetTruist initiated coverage of Alkermes Plc with a rating of Buy and set a new price target of $55.00
- PRAlkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research— Data From Vibrance-1 Phase 2 Study Lancet Neurology Publication Evaluating Alixorexton in Narcolepsy Type 1 and Additional Data From Long-Term Extension Study in Narcolepsy Type 1 and Type 2 to be Shared in Oral Presentation — — Detailed Positive Results From REVITALYZSM Phase 3 Study Evaluating LUMRYZ in Adults With Idiopathic Hypersomnia to be Shared in Oral Presentation — Alkermes plc (NASDAQ:ALKS) today announced plans to present two oral presentations and six posters from its industry-leading portfolio of sleep medicine research at the European Sleep Research Society’s (ESRS) 28th Congress, Sleep Europe 2026, taking place Oct. 20-23, 2026 in Maastricht, the Netherlands. The compa
- INSIDERSEC Form 4 filed by Alkermes plc4 - Alkermes plc. (0001520262) (Issuer)
- INSIDERSEC Form 4 filed by Alkermes plc4 - Alkermes plc. (0001520262) (Issuer)
- INSIDEREVP, CLO, Alkermes, Inc. Gaffin David Joseph sold $83,455 worth of Ordinary Shares (2,034 units at $41.03) as part of a pre-agreed trading plan, decreasing direct ownership by 0.91% to 221,388 units (SEC Form 4)4 - Alkermes plc. (0001520262) (Issuer)
- SECAlkermes plc filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Alkermes plc. (0001520262) (Filer)
- PRAlkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)— ALKS 7290 is the First Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful Improvements in ADHD Symptoms in Adults — — ALKS 7290 Was Generally Well Tolerated at All Doses Tested in Healthy Volunteers and Adults With ADHD — — Phase 2 Study of ALKS 7290 in Adults With ADHD is Enrolling, Data Expected in 2027 — Alkermes plc (NASDAQ:ALKS) today announced positive topline results from a phase 1 proof-of-concept study evaluating ALKS 7290, the company’s novel, investigational orexin 2 receptor (OX2R) agonist in development for the treatment of attention-deficit hyperactivity disorder (ADHD). The study evaluated the safety and tolerability (primary objective) and pharmacokinetic
- INSIDERSEC Form 3 filed by new insider Whitaker Anne Clem3 - Alkermes plc. (0001520262) (Issuer)
- SECAlkermes plc filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Alkermes plc. (0001520262) (Filer)
- PRAlkermes Announces Appointment of Anne C. Whitaker to Board of DirectorsAlkermes plc (NASDAQ:ALKS) today announced the appointment of a new independent director, Anne C. Whitaker, to the company’s Board of Directors (the Board). Ms. Whitaker is a seasoned biopharmaceutical executive and experienced board director who brings deep commercial and operational expertise, as well as a proven track record of driving growth and transformation across global pharmaceutical and biotechnology organizations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260915381220/en/Anne C. Whitaker "Anne joins our Board at a defining time for Alkermes," said Blair Jackson, President and Chief Executive Officer of Alkermes.
- PRAlkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program— Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project — — Areas of Interest Expanded to Include Narcolepsy and Idiopathic Hypersomnia in Addition to Schizophrenia and Bipolar I Disorder — — Stage One Submission Period Runs From Sept. 11, 2026 Through Oct. 16, 2026 — Alkermes plc (NASDAQ:ALKS) today announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards® program on Friday, Sept. 11, 2026. Now in its ninth year, this competitive grant program is designed to support the next generation of researchers working on the front lines to advance our understanding of diseases in the field of neuroscience. Building on pri
- PRTortugas Neuroscience Announces Appointment of Jim Frates to Board of DirectorsTortugas Neuroscience ("Tortugas"), a clinical-stage central nervous system (CNS)-focused biotech company developing medicines with clinically validated mechanisms of action in indications with both substantial patient populations and high unmet need, today announced the appointment of Jim Frates to its Board of Directors and as Chair of the Audit Committee. A highly experienced biopharmaceutical leader who has served as chief financial officer (CFO) for multiple public and private biotechnology companies, Frates currently serves as CFO of Amylyx Pharmaceuticals (NASDAQ:AMLX). "Jim’s wealth of experience in CNS drug development, coupled with his deep financial acumen, will be invaluable t
- INSIDEREVP, CLO, Alkermes, Inc. Gaffin David Joseph sold $97,652 worth of Ordinary Shares (2,034 units at $48.01) as part of a pre-agreed trading plan, decreasing direct ownership by 0.90% to 223,422 units (SEC Form 4)4 - Alkermes plc. (0001520262) (Issuer)
- INSIDEREVP R&D, Chief Medical Officer Hopkinson Craig C. exercised 5,000 units of Ordinary Shares at a strike of $24.59 and sold $422,874 worth of Ordinary Shares (9,000 units at $46.99) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 65,389 units (SEC Form 4)4 - Alkermes plc. (0001520262) (Issuer)
- PRThe Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1– Alixorexton Demonstrated Statistically Significant and Clinically Meaningful Improvements in Wakefulness and Cataplexy – – At All Doses Tested, Alixorexton Demonstrated Clinically Meaningful Improvements in Patient-Reported Outcomes Related to Disease Severity, Fatigue, Cognition and Health-Related Quality of Life – – Alixorexton Was Generally Well Tolerated at All Doses Tested – Alkermes plc (NASDAQ:ALKS) today announced the publication of data from the Vibrance‑1 phase 2 study of alixorexton in adults with narcolepsy type 1 (NT1) in The Lancet Neurology. Alixorexton is a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of NT
- INSIDERSVP, Chief Commercial Officer Nichols Christian Todd sold $372,937 worth of Ordinary Shares (7,576 units at $49.23) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 102,193 units (SEC Form 4)4 - Alkermes plc. (0001520262) (Issuer)
- SECAlkermes plc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Alkermes plc. (0001520262) (Filer)
- INSIDERSEC Form 4 filed by President & CEO, Alkermes plc Jackson Blair Curtis4 - Alkermes plc. (0001520262) (Issuer)
- INSIDERDirector Snyderman Nancy Lynn Md exercised 44,472 units of Ordinary Shares at a strike of $46.72 and sold $2,239,076 worth of Ordinary Shares (44,472 units at $50.35) (SEC Form 4)4 - Alkermes plc. (0001520262) (Issuer)
- INSIDEREVP R&D, Chief Medical Officer Hopkinson Craig C. sold $437,220 worth of Ordinary Shares (9,000 units at $48.58) as part of a pre-agreed trading plan and exercised 5,000 units of Ordinary Shares at a strike of $24.48, decreasing direct ownership by 5% to 69,389 units (SEC Form 4)4 - Alkermes plc. (0001520262) (Issuer)
- INSIDEREVP, CLO, Alkermes, Inc. Gaffin David Joseph sold $98,812 worth of Ordinary Shares (2,034 units at $48.58) as part of a pre-agreed trading plan, decreasing direct ownership by 0.89% to 225,456 units (SEC Form 4)4 - Alkermes plc. (0001520262) (Issuer)
- SECAmendment: Alkermes plc filed SEC Form 8-K: Leadership Update8-K/A - Alkermes plc. (0001520262) (Filer)
- SECSEC Form S-8 filed by Alkermes plcS-8 - Alkermes plc. (0001520262) (Filer)
- SECSEC Form 10-Q filed by Alkermes plc10-Q - Alkermes plc. (0001520262) (Filer)
- SECAlkermes plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Alkermes plc. (0001520262) (Filer)
ALKS FAQ
7 questionsWhat does Alkermes plc do?
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA...Where does ALKS stock trade?
Alkermes plc (ALKS) is listed on NASDAQ.What sector and industry is ALKS in?
Alkermes plc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Alkermes plc go public?
Alkermes plc (ALKS) completed its IPO in 1991.What are analysts saying about ALKS?
Alkermes plc has had 8 recent analyst actions on file. The most recent action was from Truist: Buy on 2026-10-16. Recent price targets range from $3800.00 to $4500.00.What companies are similar to ALKS?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ALKS side-by-side with any of them on Quantisnow.How can I track ALKS on Quantisnow?
Quantisnow aggregates Alkermes plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ALKS to receive live email and push alerts on every new disclosure.